Background {#Sec1}
==========

Prostate cancer was the most common cancer diagnosed in men worldwide in 2015 \[[@CR1]\]. With the exclusion of skin cancers, it represents 20% of all malignancies diagnosed in Italian males 50 years old or older \[[@CR2]\]. Survival rates after a prostate cancer diagnosis continue to rise; approximately 89% of Italian patients are still alive 5 years after diagnosis, with North-western regions showing better rates with respect to Southern ones \[[@CR2]\].

Clinical cancer researchers and oncologists recognize the importance of measuring survival and the clinical effects of treatments as well as patients' quality of life in terms of subjective perceptions of symptoms, including physical, emotional and social functions \[[@CR3], [@CR4]\]. The increasing numbers of men with prostate cancer diagnoses and rising life expectancies underscore the importance of evaluating the quality of life of these patients \[[@CR5], [@CR6]\]. A number of studies have demonstrated that prostate cancer and its treatments affect physical and psychological health, as well as urinary, bowel and sexual function, with effects that seem to differ depending on the stage of the disease and the treatment being given \[[@CR5], [@CR7]\].

The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an ongoing study that is monitoring a sample population of Italian patients who were enrolled at the time they were diagnosed as new cases of prostate cancer. It aims to analyze the quality of life and general psychological and physical health parameters in real-world treatment situations during a 60 month study period. The current article reports on the health and quality of life registered at the study's baseline when the patients were newly diagnosed with prostate cancer.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The Pros-IT CNR study design has been described elsewhere \[[@CR8]\]. Briefly, the Pros-IT CNR is a multicenter, prospective study that aims to monitor the quality of life of a sample of Italian male patients 18 years and older who were diagnosed with biopsy-verified treatment-naïve prostate cancer after September 1, 2014.

Ninety-seven centers including 51 Urology, 39 Radiation Oncology and 7 Oncological facilities located throughout Italy were actively involved in the enrollment phase. The baseline questionnaires were administered at the time prostate cancer was diagnosed. Six follow-up evaluations 6, 12, 24, 36, 48 and 60 months after the original diagnostic assessment were scheduled for the patients.

Ethics {#Sec4}
------

The Pros-IT CNR study protocol was approved by the Ethics Committee of the clinical coordinating center located at the Sant'Anna Hospital (Como, Italy; register number 45/2014). It was also approved by the Ethics Committees of each of the other participating centers. The study was carried out in accordance with the principles of the Declaration of Helsinki; all the participants gave informed consent.

Outcomes measures {#Sec5}
-----------------

Patients' quality of life was evaluated using the validated Italian version of the University of California Los Angeles-Prostate Cancer Index (Italian UCLA-PCI; \[[@CR9]\]) and the validated version of the Short Form Health Survey (SF-12 Standard v1 scale; \[[@CR10]\]). Both questionnaires were recommended for use in men with prostate cancer by the authors of a recent systematic review \[[@CR11]\]. The UCLA-PCI which received high ratings for its psychometric properties (content validity, internal consistency, construct validity and reproducibility), was recommended to evaluate health-related quality of life in prostate cancer patients. UCLA-PCI specifically evaluates urinary function and bother (UF, UB), bowel function and bother (BF, BB), and sexual function and bother (SF, SB). Scores range from 0 to 100, with higher score indicating better conditions.

SF-12 received high ratings for its criterion validity, construct validity, reproducibility, and interpretability; it was also recommended in view of its shortness \[[@CR11]\]. The patients' Physical and mental quality of life (Physical Component Summary (PCS) and Mental Component Summary (MCS), respectively) were evaluated using the SF-12 and possible scores range from 0 to 100, with 100 indicating best self-perceived health. Patients, who were originally evaluated at the time of diagnosis/enrollment, and are re-assessed at each of the appointments scheduled over the 60-month study period.

Data collection {#Sec6}
---------------

The participating centers identified eligible patients who were newly diagnosed with prostate cancer. After signing the informed consent form, a baseline Data Collection Form (DCF) was completed by the referring specialist using a web-platform that was specifically created for the study. The Italian version of the UCLA-PCI questionnaire was, instead, printed and completed by each patient privately, and then returned to the specialist who loaded the responses into the web-platform.

Statistical analysis {#Sec7}
--------------------

The missing baseline data were analyzed without imputation of missing data.

Categorical variables are presented as numbers and percentages. Continuous variables are reported as means and standard deviations (SD) or medians and interquartile ranges for skewed variables. Normal distributions of continuous variables were tested using the Shapiro-Wilk test.

The patients' overall quality of life, assessed using the SF-12 (PCS and MCS), and their quality of life linked to urinary, bowel and sexual function, assessed using the Italian version of the UCLA-PCI, were analyzed in relation to demographic characteristics, risk factors and disease-staging using a Generalized Linear Model (GLM) on rank-transformed data, adjusting for age at diagnosis.

Multivariable logistic regression models were defined, with outcomes the PCS and MCS SF-12 scores as well as the urinary, bowel and sexual functions of the UCLA-PCI, dichotomized according to the first quartile of their distribution (Q1). Each model was adjusted for age at diagnosis (years), education (lower secondary school diploma or less vs high school diploma or University degree), marital status (married or cohabitating vs widowed, divorced or single), geographical area of residence (northern regions of Italy vs central or southern regions), Body Mass Index (BMI; normal weight vs overweight or obesity), smoking status (current smoker vs former or never), diabetes mellitus, having three or more moderate/severe comorbidities, T stage (T1 vs T2 or T3-T4) and Gleason score at diagnosis (6 vs 3 + 4, 4 + 3, 8+).

All statistical tests were two-tailed, and *p*-values \< 0.05 were considered statistically significant. All the analyses were performed using the SAS 9.4 statistical software.

Results {#Sec8}
=======

One thousand seven hundred fifty-three patientswith a biopsy-verified prostate cancer were originally enrolled. Forty-eight protocol violations were registered in relation to inclusion criteria: diagnoses were formulated before September 1, 2014 for 35 patients and 13 were not naïve to prostate cancer treatments. Excluding those patients, our sample was made up of 1705 patients: 949 (55.7%) were enrolled in Urology, 717 (42.1%) in Radiation Oncology and 39 (2.3%) in Oncological Departments.

More than half of the participants were residing at the time of diagnosis in Northern Italy, about a quarter in Central Italy and the rest in Southern regions of the country. A "health migration" phenomenon was noted in these patients, as many travelled to centers located in the North to undergo diagnosis and/or treatment. In fact, 13.7 and 9% of patients residing in the South and Central areas, respectively, were enrolled at centers located in the North.

Socio-demographic characteristics {#Sec9}
---------------------------------

The main socio-demographic data are presented in Table [1](#Tab1){ref-type="table"}. The patients' mean age at diagnosis was 68.9 ± 7.4 years. Almost 12% of the participants had a university degree, 36% had a high school diploma, and almost 30% had completed elementary school or had no study degree. Eighty-five percent of the participants were married or cohabiting. More than 90% of the participants were living with other members of their family such as a spouse and/or children. Approximately three-quarters were retired.Table 1Socio-demographic characteristics and anamnestic data of the participants of the Pros-IT CNR study at the time they were diagnosed with prostate cancer*n* = 1705Socio-demographic characteristics at diagnosis Age at diagnosis, years  mean ± SD68.9 ± 7.4  min, max43, 86 Education, n (%)  University degree103 (12.0)  High school diploma596 (35.6)  Lower secondary school diploma393 (23.5)  Elementary license or less485 (28.9) Marital status, n (%)  Married or cohabiting1442 (84.9)  Widowed98 (5.8)  Separated, divorced or single159 (9.4) Living arrangements, n (%)  With spouse and/or children1535 (90.3)  Alone165 (9.7) Work condition, n (%)  Retired1263 (74.7)  Still working398 (23.6)  Unemployed29 (1.7)Anamnestic data at diagnosis BMI, n (%)  Under/normal weight (\< 25 kg/m^2^)568 (34.2)  Overweight (25--29.9 kg/m^2^)832 (50.1)  Obesity (≥30 kg/m^2^)260 (15.7) Smoking status, n (%)  Current smoker230 (13.8)  Former smoker688 (41.3)  Never smoker747 (44.9) Family history of prostate cancer, n (%)286 (17.0) Family history of breast cancer, n (%)80 (5.8) Family history of ovarian cancer, n (%)25 (2.1) Diabetes mellitus, n (%)263 (15.5) Patients reporting moderate, severe or extremely severe impairment for individual CIRS items, n (%)  Cardiac322 (19.0)  Hypertension17 (1.0)  Vascular, haematological464 (27.3)  Respiratory61 (3.6)  Eye, ear, nose and throat146 (8.6)  Upper gastrointestinal236 (13.9)  Lower gastrointestinal88 (5.2)  Hepatic110 (6.5)  Renal86 (5.1)  Other genitourinary51 (3.0)  Musculoskeletal, integumentary82 (3.0)  Neurological, excluding dementia174 (10.4)  Endocrine, metabolic83 (4.9)  Psychiatric, behavioural31 (1.8)*SD* Standard Deviation, *CIRS* Cumulative Illness Rating Scale

Anamnestic data {#Sec10}
---------------

More than half of the patients were overweight and had a BMI between 25 and 29.9 kg/m^2^ (Table [1](#Tab1){ref-type="table"}). Almost 14% declared that they were current smokers, while 41% were former smokers.

Seventeen percent of the patients reported having a family history of prostate cancer; 5.8 and 2.1%, respectively, reported family breast and ovarian cancer history. The mean age at the diagnosis of prostate cancer in the participants with a family history of the disease was significantly lower than that in those without one (66.8 ± 8.3 vs 69.3 ± 7.2, *p* \< 0.0001).

Two hundred sixty three patients (15.5%) declared that they had diabetes mellitus. Four hundred sixty-four of the patients (27.3%) reported having moderate, severe or extremely severe diseases, as defined by the Cumulative Illness Rating Scale (CIRS; \[[@CR12]\]), of the vascular, lymphatic or hematopoietic system; 322 (19.0%) referred having a disease of the cardiac system, 236 (13.9%) of the gastrointestinal apparatus and 174 (10.3%) of the neurological system, excluding dementia.

At enrollment, more than 70% of the participants were taking at least one medication; the median number of drugs assumed was three (interquartile range IQ 1--4). Precisely 53.7% were taking drugs for the circulatory system, 27% of the participants were receiving antithrombotic agents, 25.4% were medication for the digestive system and metabolism (16.4% for acidosis, 10.6% hypoglycemic drugs). About one quarter of the enrolled patients (22.6%) were taking urological drugs for lower urinary tract symptoms or for erectile dysfunction.

Diagnosis {#Sec11}
---------

The median prostate-specific antigen (PSA) level at diagnosis was 7.2 ng/mL (IQ 5.2--10.6). Approximately half of the study participants had a T1 clinical stage (786, 48%), 38.6 and 11.4% had a T2 or T3-T4clinical stage, respectively. The Gleason score for prostate biopsy tissue was six for 718 patients (42.8%), 3 + 4 for 381 (22.7%), 4 + 3 for 233 (13.9%) and 8+ for 349 patients (20.8%). The association of age at diagnosis with both the clinical T stage and the Gleason score was significant (*p* \< 0.0001 for trend; Fig. [1a, b](#Fig1){ref-type="fig"}).Fig. 1Clinical T staging (**a**) and Gleason score (**b**) of the participants of the Pros-IT CNR study by age classes at diagnosis

Quality of life: SF-12 {#Sec12}
----------------------

Complete responses to the SF-12 were available for 1664 participants (data was missing for 2.4% of the participants). The mean PCS value for the entire study population was 51.6 ± 7.5; the mean MCS value was 49.3 ± 9.7. While mean PCS scores tended to be lower in the oldest patients (*p* \< 0.0001), the mean MCS scores tended to be higher in the oldest patients (*p* = 0.0059).

Table [2](#Tab2){ref-type="table"} outlines the mean PCS and MCS values at diagnosis analyzed together with other characteristics of the participants. The characteristics associated with lower PCS scores in the multivariable logistic regression model were age (Odds Ratio OR 1.06 for each year of age, 95% Confidence Interval CI 1.04--1.08, *p* \< 0.0001), obesity (OR 1.84, 95% CI 1.27--2.65, *p* = 0.0012), the presence of three or more moderate/severe comorbidities (OR 2.75, 95% CI 2.01--3.76, p \< 0.0001) and a Gleason score at diagnosis of 8+ (OR = 1.44, 95% CI 1.02--2.05, *p* = 0.0401). Living in Southern regions of Italy and being widowed or single were also associated with lower PCS scores in the multivariable model (OR = 1.69, 95% CI 1.23--2.33, *p* = 0.0013 and OR = 1.42, 95% CI 1.02--1.98, p = 0.040, respectively).Table 2Demographic data and responses to the physical (PCS) and mental components (MCS) of the SF-12 of the participants of the Pros-IT CNR study at the time they were diagnosed with prostate cancerPCS\*p-valueMCS\*p-valueAge at diagnosis (years)\< 0.0001^§^0.0058^§^  \< 6054.4 ± 6.247.3 ± 9.9 60--6452.8 ± 6.648.5 ± 9.7 65--6952.2 ± 6.850.2 ± 9.3 70--7451.1 ± 7.749.5 ± 10.1 75--7950.1 ± 8.049.9 ± 9.3 80+48.1 ± 10.249.9 ± 9.0Education0.44600.5036 University degree52.7 ± 6.649.6 ± 9.4 High school diploma52.1 ± 7.249.0 ± 9.5 Lower secondary school diploma51.2 ± 7.949.0 ± 9.8 Elementary license or less51.0 ± 7.950.0 ± 9.8Marital status0.55750.4830 Married or cohabiting51.8 ± 7.449.5 ± 9.4 Widowed51.1 ± 7.749.1 ± 10.2 Separated, divorced or single51.1 ± 8.048.0 ± 11.0Geographical area of residence0.00020.0991 North Italy51.7 ± 7.5^a^49.9 ± 9.6 Central Italy52.3 ± 7.2^b^49.0 ± 9.7 Southern Italy50.4 ± 7.8^ab^48.7 ± 9.8BMI\< 0.00010.3796 Under/normal weight (\< 25 kg/m^2^)52.0 ± 7.5^a^49.1 ± 9.7 Overweight (25--29.9 kg/m^2^)52.0 ± 7.1^b^49.5 ± 9.5 Obesity (≥30 kg/m^2^)49.7 ± 8.4^ab^49.7 ± 9.9Smoking status0.15760.4419 Non-smoker or former51.6 ± 7.649.4 ± 9.6 Current smoker51.9 ± 7.248.4 ± 10.1Diabetes mellitus\< 0.00010.1894 No52.0 ± 7.349.4 ± 9.7 Yes49.6 ± 8.449.0 ± 9.6Number of moderate/severe comorbidities (according to CIRS)\< 0.0001\< 0.0001 0--252.5 ± 6.749.8 ± 9.4 3+47.0 ± 9.946.8 ± 10.4T staging at diagnosis0.8226\< 0.0001 T152.0 ± 7.250.4 ± 9.3^ab^ T251.6 ± 7.648.7 ± 9.6^a^ T3 or T451.1 ± 7.948.6 ± 10.1^b^Gleason score at diagnosis0.34090.1599 652.1 ± 7.049.6 ± 9.3 3 + 451.9 ± 7.350.0 ± 9.5 4 + 351.6 ± 7.848.6 ± 10.3 8+50.7 ± 8.348.7 ± 10.1^\*^mean ± SD^§^p-value from test for trend^a,\ b^significant post-hoc (*p* \< 0.05 adjusting for age at diagnosis)

The characteristics associated with lower MCS scores in the multivariable logistic model were younger age (OR = 0.97, 95% CI 0.96--0.98, p = 0.0012), the presence of three or more moderate/severe comorbidities (OR 1.95, 95% CI 1.42--2.70, *p* \< 0.0001), a T-score at diagnosis that was higher than T1 (T2 vs T1 OR 1.51, 95% CI 1.15--1.98, *p* = 0.0029; T3-T4 vs T1 OR 1.62, 95% CI 1.06--2.48, *p* = 0.0253).

Quality of life: UCLA-PCI {#Sec13}
-------------------------

Complete responses to the UCLA-PCI were available for 1645 participants (3.5% missing data). At the time prostate cancer was diagnosed, urinary function was good (93.2 ± 15.7) and urinary bother scores were low (88.5 ± 23.3). Four point 9 % of the study participants reported using at least one safety pad daily to control urinary loss; the increase with age was not significant (*p* = 0.1943): the percent ranged from 3.2% in the patients younger than 65 to 5.8, 5.3 and 5.4% in the patients between 65 and 69, 70--74 and 75-older, respectively. The use of a daily safety pad to control urinary loss was significantly associated with lower urinary bother scores (45.7 ± 29.3 vs 90.7 ± 20.7, p \< 0.0001).

Bowel function and bother scores on the UCLA-PCI were generally good (93.6 ± 13.2 and 93.3 ± 18.3, respectively), and less than 3% of the participants reported a moderate or severe problem attributable to bowel function. The mean sexual function and bother scores were 48.6 ± 32.2 and 64.1 ± 35.0, respectively. Twenty-six point 7 % of the participants declared that their sexual function was a moderate/large problem: the percentages ranged from 22.9 to 23.8% to 29.8 and 30.5% in the patients younger than 65, between 65 and 69, 70--74 or 75 or older respectively (*p* = 0.0044).

Age was the main characteristic associated with prostate cancer scores (Fig. [2](#Fig2){ref-type="fig"}; Table [3](#Tab3){ref-type="table"}), also in the multivariable logistic regression models; the *p*-values for trend with increasing age were statistically significant for every health aspect evaluated by UCLA-PCI.Fig. 2Mean responses regarding urinary, bowel and sexual function and bother (UCLA-PCI) of the participants of the Pros-IT CNR study by age classes at diagnosisTable 3Demographic data and responses regarding urinary, bowel and sexual function and bother to the UCLA-PCI of the participants of the Pros-IT CNR study at the time they were diagnosed with prostate cancerUrinary Function\**p*-valueUrinary Bother\**p*-valueBowel Function\**p*-valueBowel Bother\**p*-valueSexual Function\**p*-valueSexual Bother\**p*-valueAge at diagnosis0.0015^§^0.0030^§^0.0058^§^0.0167^§^\< 0.0001^§^\< 0.0001^§^  \< 60 years95.5 ± 12.493.3 ± 18.194.7 ± 12.494.9 ± 17.574.3 ± 25.074.8 ± 34.6 60--6494.3 ± 14.288.7 ± 23.794.5 ± 13.494.3 ± 15.763.2 ± 27.866.9 ± 34.6 65--6993.3 ± 16.388.9 ± 23.594.7 ± 11.494.6 ± 16.051.2 ± 30.465.3 ± 32.8 70--7492.2 ± 16.686.9 ± 24.592.9 ± 13.792.1 ± 19.643.1 ± 30.259.5 ± 35.1 75--7992.3 ± 16.387.5 ± 24.292.8 ± 13.993.3 ± 18.933.2 ± 29.558.5 ± 36.4 80+92.2 ± 16.788.0 ± 23.991.9 ± 16.287.1 ± 25.123.0 ± 25.370.3 ± 33.6Education0.82550.78330.38670.14110.23390.4686 University degree94.3 ± 14.289.3 ± 22.195 ± 11.293.1 ± 17.256.8 ± 32.667.7 ± 35.3 High school diploma93.6 ± 15.488.2 ± 23.893.4 ± 1392.8 ± 18.752.2 ± 31.863.6 ± 35.2 Lower secondary school diploma92.8 ± 15.788.9 ± 23.594.4 ± 12.494.5 ± 16.949.6 ± 32.566.2 ± 34.3 Elementary or less92.4 ± 16.888.3 ± 23.492.8 ± 14.792.9 ± 19.339.9 ± 30.561.8 ± 35.2Marital status0.17200.67390.01580.64900.54330.6904 Married/cohabiting93.4 ± 15.688.7 ± 23.293.9 ± 13.1^a^93.5 ± 18.149.1 ± 32.263.9 ± 35.1 Widowed91.7 ± 1588.7 ± 22.992.7 ± 14.291.1 ± 21.940.6 ± 29.963.3 ± 34.5 Separated, divorced, single91.9 ± 17.187.1 ± 25.191.5 ± 13.9^a^93 ± 18.348.4 ± 32.766.6 ± 34.8Geographical residence0.07920.09880.16800.28180.0651\< 0.0001 North Italy93.2 ± 15.388.3 ± 23.293.5 ± 12.893.1 ± 18.347.5 ± 32.367.8 ± 34.1^ab^ Central Italy92.7 ± 16.590.2 ± 22.194.7 ± 12.394.2 ± 17.651.4 ± 31.358.8 ± 35.3^a^ South Italy92.5 ± 1686.9 ± 25.593 ± 14.992.8 ± 19.146.7 ± 33.260 ± 36.3^b^BMI0.82190.39620.02900.63730.00120.3423 Under/normal weight (\< 25 kg/m^2^)93 ± 16.288.7 ± 23.994 ± 12.6^a^93.3 ± 18.350.3 ± 32^a^65.3 ± 34.8 Overweight (25--29.9 kg/m^2^)93.1 ± 15.688.7 ± 22.994.1 ± 12.5^b^93.6 ± 17.648.9 ± 32.3^b^64.1 ± 34.8 Obesity (≥30 kg/m^2^)93.3 ± 15.187.4 ± 23.791 ± 16.5^ab^91.8 ± 21.043.4 ± 32^ab^61.8 ± 36.1Smoking status0.30110.23750.52010.80610.65220.9697 Non-smoker or former92.9 ± 1688.1 ± 23.993.4 ± 13.593.1 ± 18.647.8 ± 32.263.8 ± 35.2 Current smoker94.4 ± 14.391.1 ± 20.494.7 ± 11.393.9 ± 16.653.6 ± 31.266.1 ± 34.0Diabetes mellitus0.38370.26070.62160.0585\< 0.00010.6154 No93.3 ± 15.788.9 ± 23.093.8 ± 12.993.7 ± 17.750.5 ± 32.064.5 ± 34.9 Yes92.6 ± 15.986.9 ± 25.092.9 ± 14.691.1 ± 21.438.2 ± 31.062.0 ± 35.7N. of moderate/severe comorbidities (CIRS)0.07740.00720.0001\< 0.0001\< 0.00010.1873 0--293.4 ± 15.589.4 ± 22.394.2 ± 12.594.5 ± 16.350.8 ± 31.964.9 ± 34.9 3+91.9 ± 16.683.8 ± 27.890.3 ± 16.386.5 ± 26.135.7 ± 30.760.2 ± 35.4T staging at diagnosis0.10700.01330.26580.5184\< 0.00010.4077 T194.2 ± 1490.3 ± 2294.6 ± 12.294 ± 17.255.7 ± 30.6^a^66.6 ± 33.8 T292.8 ± 16.287.2 ± 24.493.6 ± 13.093.0 ± 18.343.5 ± 31.7^b^62.8 ± 34.8 T3 or T490.7 ± 1986.4 ± 24.393.5 ± 13.693.2 ± 19.537.1 ± 32.3^ab^63.6 ± 36.9Gleason score at diagnosis0.66530.28940.82310.5100\< 0.00010.5015 693.9 ± 14.490.1 ± 21.694.3 ± 12.294.3 ± 16.654.8 ± 30.366.0 ± 34.1 3 + 493.3 ± 16.488.9 ± 23.393.8 ± 12.592.8 ± 18.348.8 ± 31.762.7 ± 35.5 4 + 393.7 ± 13.486.7 ± 25.093.4 ± 13.193.8 ± 17.044.9 ± 32.560.6 ± 35.9 8+91.6 ± 18.587.1 ± 24.893 ± 14.792.1 ± 21.239 ± 33.364.5 ± 35.7^\*^mean ± SD^§^p-value from test for trend^a,\ b^significant post-hoc (p \< 0.05 adjusting for age at diagnosis

Variables significantly associated with lower scores on sexual function in the multivariable models were age (OR 1.10, 95% CI 1.08--1.13, *p* \< 0.0001), diabetes (OR = 1.40, 95% CI 1.01--1.96, *p* = 0.0485), three or more moderate/severe comorbidities according to CIRS (OR 1.55, 95% CI 1.11--2.16, *p* = 0.0103), T2 or T3-T4 at diagnosis (OR = 1.42, 95% CI 1.06--1.89, *p* = 0.0185, and OR = 1.75, 95% CI 1.14--2.69, *p* = 0.0093, vs T1, respectively) and a Gleason score of eight or more (OR = 2.03, 95% CI 1.42--2.92, *p* = 0.0001).

Discussion {#Sec14}
==========

The PROS-IT CNR Study allows to assess the quality of life of males diagnosed as new cases of prostate cancer in Italy. More than half of the patients reside in Northern Italy, a fact that is linked to the geography of the centers, which all voluntarily agreed to participate in the study. Half, in fact, are located in the North; approximately a fourth are located in Central Italy and the rest in the Southern part of the country. According to the last report of the Italian Association of Cancer Registry (AIRTUM), the standardized incidence of prostate cancer was inferior in the Southern and Central regions with respect to that in the Northern ones (68 and 85.7 vs 99.8 per 100,000 men) \[[@CR2]\]. Official records also show that while the Southern part of Italy is characterized by a lower incidence rate of prostate cancer, it nonetheless also registers a shorter survival rate. Our study will provide evidence on potential delay in the diagnosis of prostate cancer in South Italy, which could explain these epidemiological trends.

The patients participating in the Pros-IT CNR study were found to be characterized by a higher education with respect to data referring to the general population of males over 75 reported by the Italian Statistics Institute (ISTAT) \[[@CR13]\]. While 12% of the men enrolled in our study had a university degree, only 7% of the general population did so. While 30% of the participants completed grade school or had no official schooling, 48.6% of the general male elderly population did so. The differences in educational status of the participants and the general population, seem to suggest that socio-economic characteristics might be associated to the risk of prostate cancer in the Italian population. We cannot however exclude a selection bias as more highly educated males may have agreed to participate in the study.

The mean score physical SF-12 component score was 51.7, which was higher than that described by the ISTAT in males between 65 and 74 (48.4) or those over 75 (41.5). The scores on the emotional-psychological SF-12 component in the participants were consistent with those reported by the ISTAT in males between 65 and 74 and slightly higher than those calculated for men over 75 \[[@CR13]\]. These results disagree to some extent with what has been reported by other studies. For example, both the investigators of the ProtecT trial and a review on prostate cancer and health-related quality of life, reported scores on the two SF-12 components in just diagnosed patients that were consistent with those in the population at large \[[@CR5], [@CR7]\]. Moreover, according to other studies, just diagnosed with prostate cancer patients had lower scores on the emotional-psychological component with the respect to those in the general population \[[@CR14], [@CR15]\]. Again, these results could be explained by the higher level of education of the participants in our sample compared to that of the general population, a factor that is usually associated to an overall better physical and emotional health.

The scores on the physical component and thus concerning the perception of physical health were worse, in our study, in the older age-groups, while those concerning emotional-psychological status tended to be worse in the youngest age-group, suggesting, just as has been point out in other studies, that a certain amount of psyco-emotional adjustment takes place with aging \[[@CR16], [@CR17]\].

It is interesting that worse emotional-psychological component scores were associated to worse T classes at diagnosis regardless of age or other confounding factors such as comorbidities. Likewise, worse T or Gleason scores at diagnosis were associated to worse scores on sexual function, although in some studies men with localized prostate cancer reported more sexual problems with respect to same-age peers without cancer \[[@CR3]\].

Approximately 5% of the patients included in our study declared that they used at least one safety pad daily to control urinary loss. That percentage did not change in the older patients, but it did when there were other urinary disturbances. This baseline finding is of primary relevance when post-treatment continence is being defined and evaluated.

The Pros-IT CNR study has several strengths, including its multidisciplinary approach and its prospective design. The study's longitudinal design that foresees monitoring the participants for 60 months from the time of diagnosis, will allow to evaluate the disease's evolution over time and the patients quality of life. One of the study's limitations instead is connected to the fact that centres were involved on a voluntary basis and a selection bias cannot be excluded.

Conclusions {#Sec15}
===========

The importance of the results presented here is twofold: they draw a profile of the general state of health and the subjective perception of quality of life of patients who have just been diagnosed with prostate cancer. Moreover, they underscore the patients' characteristics at diagnosis that are relevant for appreciating the variations over time of their quality of life. More detailed knowledge about patients' pre-treatment status and perception of health and quality of life will be essential to evaluate their response to treatment and to permit us to compare our data with those reported by other studies.
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